E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-Small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 05 May 2015
At a glance
- Drugs Lenvatinib (Primary) ; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Eisai Co Ltd
- 11 Aug 2011 Actual end date (July 2011) added as reported by ClinicalTrials.gov.
- 11 Aug 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Feb 2010 Planned end date changed from 1 Mar 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov.